Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial

Overview of attention for article published in BMC Cancer, October 2016

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 X post from an account with 1,548 followers.

Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepa... https://t.co/bxshrVyIFN #cancer

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.